Rank Company 1 GlaxoSmithKline 2 Genzyme 3 Roche 4 Astellas Pharma 5 Pfizer 6 Bristol-Myers Squibb 7 Merck KGaA 8 GlaxoSmithKline 9 GlaxoSmithKline 10 Nycomed
Deal Type In-licensed In-licensed In-licensed In-licensed In-licensed In-licensed In-licensed
Product Almorexant (ACT-078573) Mipomersen R7334 CTS-21166 Dimebon Elotuzumab Asonep Efflux Pump Inhibitors In-licensed Research Project In-licensed Retigabine In-licensed Veltuzumab (IMMU-106)
Deal Partner/ Product Deal Source Value($m) Actelion 3,009 Isis Pharmaceuticals 1,900 ThromboGenics 750 CoMentis 744 Medivation 725 PDL BioPharma 710 Lpath 696 655 Mpex Pharmaceuticals Valeant Pharmaceuticals 634 Immunomedics 591
Prepared By: ManasRanjanRout Pharmaceutical & Healthcare Professional New Delhi Email:
[email protected]
Deal Date J ul-08 J an-08 J un-08 Apr-08 Oct-08 Aug-08 Oct-08 J un-08 Aug-08 J ul